Tu uhevaha J Kaitu u-Lino

List of Publications by Citations

Source: https://exaly.com/author-pdf/590554/tuuhevaha-j-kaituu-lino-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers1,946
citations25
h-index39
g-index107
ext. papers2,461
ext. citations4.2
avg, IF4.8
L-index

#	Paper	IF	Citations
106	Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 356.e1-356.e15	6.4	121
105	Claudin-11 expression and localisation is regulated by androgens in rat Sertoli cells in vitro. <i>Reproduction</i> , 2007 , 133, 1169-79	3.8	117
104	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. <i>Hypertension</i> , 2015 , 66, 687-97; discussion 445	8.5	111
103	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. <i>Hypertension</i> , 2017 , 69, 457-46	8 ^{8.5}	84
102	Neutrophil depletion retards endometrial repair in a mouse model. <i>Cell and Tissue Research</i> , 2007 , 328, 197-206	4.2	69
101	Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. <i>Hypertension</i> , 2015 , 66, 1251-9	8.5	58
100	MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. <i>American Journal of Pathology</i> , 2012 , 180, 888-894	5.8	56
99	Estrogen is not essential for full endometrial restoration after breakdown: lessons from a mouse model. <i>Endocrinology</i> , 2007 , 148, 5105-11	4.8	53
98	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 287-95	2.6	45
97	Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E42	9 ⁵ 36	43
96	Reepithelialization of the uterine surface arises from endometrial glands: evidence from a functional mouse model of breakdown and repair. <i>Endocrinology</i> , 2010 , 151, 3386-95	4.8	43
95	Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner. <i>Reproduction</i> , 2015 , 149, 435-44	3.8	42
94	Role of label-retaining cells in estrogen-induced endometrial regeneration. <i>Reproductive Sciences</i> , 2012 , 19, 102-14	3	41
93	Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. <i>Scientific Reports</i> , 2017 , 7, 1819	4.9	39
92	Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. <i>Hypertension</i> , 2015 , 65, 855-62	8.5	38
91	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. <i>BMC Pregnancy and Childbirth</i> , 2016 , 16, 117	3.2	32
90	Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. <i>Reproduction</i> , 2006 , 132, 799-810	3.8	32

(2020-2013)

89	Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies. <i>Endocrinology</i> , 2013 , 154, 911-9	4.8	31	
88	PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. <i>Reproduction, Fertility and Development</i> , 2014 , 26, 351-7	1.8	28	
87	Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E936-45	5.6	27	
86	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion. <i>Hypertension</i> , 2019 , 73, 659-670	8.5	27	
85	ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. <i>American Journal of Pathology</i> , 2018 , 188, 1749-1753	5.8	26	
84	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. <i>BMJ Open</i> , 2019 , 9, e025809	3	25	
83	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. <i>PLoS ONE</i> , 2018 , 13, e0188845	3.7	25	
82	A new role for activin in endometrial repair after menses. <i>Endocrinology</i> , 2009 , 150, 1904-11	4.8	25	
81	Identification of label-retaining perivascular cells in a mouse model of endometrial decidualization, breakdown, and repair. <i>Biology of Reproduction</i> , 2012 , 86, 184	3.9	25	
80	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. <i>Hypertension</i> , 2015 , 66, 10	173 ⁸ 8 ⁵ 1	24	
79	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. <i>Molecular and Cellular Endocrinology</i> , 2015 , 413, 202-8	4.4	23	
78	Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. <i>PLoS ONE</i> , 2018 , 13, e0187082	3.7	23	
77	Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. <i>Human Reproduction</i> , 2013 , 28, 1172-80	5.7	23	
76	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. <i>EBioMedicine</i> , 2019 , 41, 636-648	8.8	22	
75	Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. <i>Journal of Reproductive Immunology</i> , 2012 , 95, 46-9	4.2	19	
74	Extracellular matrix dynamics in scar-free endometrial repair: perspectives from mouse in vivo and human in vitro studies. <i>Biology of Reproduction</i> , 2011 , 85, 511-23	3.9	19	
73	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2020 ,	6.4	19	
72	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. <i>Nature Communications</i> , 2020 , 11, 2411	17.4	18	

Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the 71 maternal blood at 28 weeksSgestation. American Journal of Obstetrics and Gynecology, 2016, 214, 521.e $^{6.52}$ 1.e $^{8.7}$ Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. 70 4.9 17 Obstetrics and Gynecology, **2013**, 122, 737-744 Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important 69 17 3.7 Functions during Embryo Development and Implantation. PLoS ONE, 2016, 11, e0163096 Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in 68 8.5 16 Placenta. Hypertension, 2017, 70, 1014-1024 Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as 67 16 3.4 measured by digital PCR. Placenta, 2014, 35, 1106-9 MT-MMPs in pre-eclamptic placenta: relationship to soluble endoglin production. Placenta, 2013, 66 16 3.4 34, 168-73 Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. 65 2.6 15 Pregnancy Hypertension, 2020, 20, 83-91 The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women. 64 3.8 15 Reproduction, 2007, 133, 309-21 Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36[weeksSqestation to predict small-for-gestational-age infants or late-onset preeclampsia: a 63 15 3.2 prospective nested case-control study. BMC Pregnancy and Childbirth, 2018, 18, 354 Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates 62 3.9 14 sFLT-1 Splice Variant Production. Biology of Reproduction, 2016, 94, 59 Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation. Reproductive 61 14 3 Sciences, 2015, 22, 852-9 MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin. 60 3.7 14 PLoS ONE, 2012, 7, e39864 Serum concentrations of soluble Flt-1 are decreased among women with a viable fetus and no 59 3.7 14 symptoms of miscarriage destined for pregnancy loss. PLoS ONE, 2012, 7, e32509 Plasma MIC-1 and PAPP-a levels are decreased among women presenting to an early pregnancy 58 3.7 14 assessment unit, have fetal viability confirmed but later miscarry. PLoS ONE, 2013, 8, e72437 The untapped potential of placenta-enriched molecules for diagnostic and therapeutic 57 14 3.4 development. Placenta, 2019, 84, 28-31 Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency 56 11.4 13 and at high risk of stillbirth. BMC Medicine, 2020, 18, 145 A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for 55 3.7 12 predictors of miscarriage. PLoS ONE, 2014, 9, e93320 ATF3 is a negative regulator of inflammation in human fetal membranes. Placenta, 2016, 47, 63-72 54 12 3.4

(2017-2017)

53	Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 635-63	19 ²	11	
52	Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. <i>Placenta</i> , 2017 , 51, 1-9	3.4	11	
51	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. <i>Reproductive Sciences</i> , 2017 , 24, 1245-1252	3	11	
50	Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location. <i>PLoS ONE</i> , 2012 , 7, e41442	3.7	10	
49	Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. <i>Reproduction</i> , 2008 , 136, 267-74	3.8	10	
48	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. <i>Placenta</i> , 2020 , 102, 10-16	3.4	10	
47	Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. <i>Human Reproduction Update</i> , 2021 , 27, 280-304	15.8	10	
46	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. <i>Placenta</i> , 2015 , 36, 932-7	3.4	8	
45	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. <i>BMJ, The</i> , 2021 , 374, n2103	5.9	8	
44	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. <i>Placenta</i> , 2020 , 95, 78-83	3.4	7	
43	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. <i>Placenta</i> , 2016 , 48, 110-118	3.4	7	
42	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. <i>Placenta</i> , 2016 , 48, 72-79	3.4	7	
41	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. <i>Placenta</i> , 2019 , 88, 1-7	3.4	6	
40	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. <i>Pregnancy Hypertension</i> , 2019 , 16, 16-25	2.6	6	
39	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. <i>Placenta</i> , 2020 , 91, 24-30	3.4	6	
38	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. <i>Pregnancy Hypertension</i> , 2016 , 6, 95-102	2.6	6	
37	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. <i>Prenatal Diagnosis</i> , 2019 , 39, 947-957	3.2	6	
36	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. <i>Pregnancy Hypertension</i> , 2017 , 10, 18-21	2.6	6	

35	Clinical tools and biomarkers to predict preeclampsia <i>EBioMedicine</i> , 2021 , 75, 103780	8.8	6
34	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. <i>Scientific Reports</i> , 2020 , 10, 18077	4.9	6
33	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. <i>Pregnancy Hypertension</i> , 2018 , 13, 1-6	2.6	5
32	Placental SEMA3B expression is not altered in severe early onset preeclampsia. <i>Placenta</i> , 2014 , 35, 1102	2 ₃ 54	5
31	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. <i>Pregnancy Hypertension</i> , 2020 , 22, 86-92	2.6	5
30	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. <i>Placenta</i> , 2021 , 105, 32-40	3.4	5
29	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. <i>Placenta</i> , 2019 , 87, 53-57	3.4	4
28	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. <i>Scientific Reports</i> , 2019 , 9, 235	4.9	4
27	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. <i>Reproductive Biology and Endocrinology</i> , 2013 , 11, 40	5	4
26	Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. <i>PLoS ONE</i> , 2013 , 8, e66339	3.7	4
25	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. <i>Placenta</i> , 2021 , 110, 24-28	3.4	4
24	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. <i>Pregnancy Hypertension</i> , 2018 , 14, 115-120	2.6	4
23	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. <i>Journal of the American Heart Association</i> , 2021 , 10, e020302	6	4
22	Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment. <i>Reproductive Sciences</i> , 2015 , 22, 1202-11	3	3
21	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018 , 29, 166-176	8.8	3
20	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
19	Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction. <i>Placenta</i> , 2020 , 95, 53-61	3.4	2
18	DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia. <i>Scientific Reports</i> , 2021 , 11, 5540	4.9	2

LIST OF PUBLICATIONS

17	A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid. <i>BMC Research Notes</i> , 2016 , 9, 335	2.3	2
16	Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies. <i>Placenta</i> , 2021 , 112, 162-	-13-4	2
15	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeksSgestation in pregnancies destined to deliver small for gestational age infants. <i>Placenta</i> , 2021 , 117, 1-4	3.4	1
14	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
13	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. <i>Scientific Reports</i> , 2021 , 11, 16595	4.9	1
12	LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. <i>Pregnancy Hypertension</i> , 2021 , 25, 255-261	2.6	1
11	PSG7 and 9 (Pregnancy-Specific El Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia <i>Journal of the American Heart Association</i> , 2022 , e024536	6	1
10	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 501-503	2	0
9	Circulating Activin A is elevated at 36 weeks Sgestation preceding a diagnosis of preeclampsia. <i>Pregnancy Hypertension</i> , 2021 , 27, 23-26	2.6	О
8	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. <i>Pregnancy Hypertension</i> , 2018 , 14, 125-130	2.6	0
7	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. <i>Placenta</i> , 2021 , 114, 22-28	3.4	О
6	Circulating SPINT1 in the second trimester is reduced among pregnancies that ends in low birthweight neonates: cohort study of 2006 pregnancies <i>American Journal of Obstetrics & amp; Gynecology MFM</i> , 2022 , 100618	7.4	О
5	Screening circulating proteins to identify biomarkers of fetal macrosomia. <i>BMC Research Notes</i> , 2019 , 12, 587	2.3	
4	A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. <i>Pregnancy Hypertension</i> , 2015 , 5, 294-7	2.6	
3	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 255-8	2.6	
2	NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. <i>Scientific Reports</i> , 2021 , 11, 20670	4.9	
1	Measuring circulating miRNAs in early pregnancy could identify fetusesSdestined to undergrow and be at increased risk of stillbirth. <i>EBioMedicine</i> , 2021 , 63, 103172	8.8	